The increased share price target by FRC is based on Ocean Biomedical's recent achievements, including positive glioblastoma study results, new patents, and financing. These developments indicate progress in the company's diversified pipeline, which targets significant global markets in oncology, fibrosis, and infectious diseases. This positive news is likely to have a short-term positive impact on OCEA's stock price.